Documents
Application Sponsors
ANDA 211533 | MSN LABS PVT LTD | |
Marketing Status
Application Products
001 | TABLET; ORAL | 10MG/5MG | 0 | DAPAGLIFLOZIN AND SAXAGLIPTIN | SAXAGLIPTIN HYDROCHLORIDE DIHYDRATE AND DAPAGLIFLOZIN |
FDA Submissions
UNKNOWN; | ORIG | 1 | TA | 2020-05-28 | STANDARD |
Submissions Property Types
CDER Filings
MSN LABS PVT LTD
cder:Array
(
[0] => Array
(
[ApplNo] => 211533
[companyName] => MSN LABS PVT LTD
[docInserts] => ["",""]
[products] => [{"drugName":"DAPAGLIFLOZIN AND SAXAGLIPTIN","activeIngredients":"SAXAGLIPTIN HYDROCHLORIDE DIHYDRATE AND DAPAGLIFLOZIN","strength":"10MG\/5MG","dosageForm":"TABLET; ORAL","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
[labels] =>
[originalApprovals] => [{"actionDate":"05\/28\/2020","submission":"ORIG-1","actionType":"Tentative Approval","submissionClassification":"","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/211533Orig1s000TAltr.pdf\"}]","notes":"> Label is not available on this site."}]
[supplements] =>
[actionDate] => 2020-05-28
)
)